JP2010523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523676A5
JP2010523676A5 JP2010503070A JP2010503070A JP2010523676A5 JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5 JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5
Authority
JP
Japan
Prior art keywords
composition
liposome
peptide
hiv
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523676A (ja
Filing date
Publication date
Priority claimed from US11/785,077 external-priority patent/US9402893B2/en
Priority claimed from US11/812,992 external-priority patent/US20080057075A1/en
Application filed filed Critical
Priority claimed from PCT/US2008/004709 external-priority patent/WO2008127651A1/en
Publication of JP2010523676A publication Critical patent/JP2010523676A/ja
Publication of JP2010523676A5 publication Critical patent/JP2010523676A5/ja
Pending legal-status Critical Current

Links

JP2010503070A 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法 Pending JP2010523676A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/785,077 US9402893B2 (en) 2005-04-12 2007-04-13 Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
US11/812,992 US20080057075A1 (en) 2005-04-12 2007-06-22 Method of inducing neutralizing antibodies to human immunodeficiency virus
US96041307P 2007-09-28 2007-09-28
PCT/US2008/004709 WO2008127651A1 (en) 2007-04-13 2008-04-11 Method of inducing neutralizing antibodies to human immunodeficiency virus

Publications (2)

Publication Number Publication Date
JP2010523676A JP2010523676A (ja) 2010-07-15
JP2010523676A5 true JP2010523676A5 (enExample) 2010-11-18

Family

ID=39864256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503070A Pending JP2010523676A (ja) 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法

Country Status (6)

Country Link
US (2) US8956627B2 (enExample)
EP (1) EP2139516A4 (enExample)
JP (1) JP2010523676A (enExample)
AU (1) AU2008239628B2 (enExample)
CA (1) CA2683752A1 (enExample)
WO (1) WO2008127651A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235507B2 (en) 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2736030A1 (en) * 2008-09-05 2010-03-11 Barton F. Haynes Method of inducing an anti-viral immune response
US9402917B2 (en) 2009-04-03 2016-08-02 Duke University Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
CA2791025A1 (en) * 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
EP2822599A4 (en) * 2012-03-05 2015-12-23 Univ Duke VACCINE FORMULATION
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5831034A (en) * 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US4994440A (en) * 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
EP0570357B1 (en) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
CN1122576A (zh) * 1993-03-11 1996-05-15 南加利福尼亚大学 免疫感染簇病毒感染的治疗策略
JPH08510751A (ja) * 1993-05-27 1996-11-12 エントレメッド インコーポレイテッド 癌及び過増殖性疾患を治療するための組成物及び方法
CA2168671C (en) * 1993-08-06 2007-04-10 Yechezkel Barenholz A method for high loading of vesicles with biopolymeric substances
HU219507B (hu) 1993-09-11 2001-04-28 Polymun Scientific Immunobiologische Forschung Gmbh. Genetikailag divergens HIV-1-törzsekkel szemben neutralizáló ellenanyagok termelődését kiváltó peptidek
CA2185129A1 (en) 1994-03-14 1995-09-21 Angeline Douvas Methods to diagnose and treat hiv-1 infection
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0822941B1 (en) * 1995-04-19 2002-06-12 Polymun Scientific Immunbiologische Forschung GmbH Monoclonal antibodies against hiv-1 and vaccines made thereof
WO1996040243A1 (en) * 1995-06-07 1996-12-19 U.S. Department Of The Army Liposomes containing human immunodeficiency virus glycoprotein and methods for use thereof
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5901306A (en) * 1997-06-23 1999-05-04 Sun Microsystems, Inc. Method and apparatus for reducing a computational result to the range boundaries of a signed 8-bit integer in case of overflow
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
AU2002340880B2 (en) 2001-09-07 2007-08-23 Polymun Scientific Immunbiologische Forschung Gmbh Peptides mimicking a cryptic epitope of GP41 HIV-1 and antibodies directed against them
US7195768B2 (en) * 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
JP4495969B2 (ja) * 2002-01-17 2010-07-07 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Hiv−1中和抗体を誘導する抗イディオタイプ抗体
US7611704B2 (en) * 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
KR20110025885A (ko) 2002-07-15 2011-03-11 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
US7906115B2 (en) * 2002-07-15 2011-03-15 Thorpe Philip E Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7455833B2 (en) * 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7790159B2 (en) * 2002-07-15 2010-09-07 Board Of Regents, The University Of Texas System Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
US7384909B2 (en) * 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US20040131622A1 (en) * 2002-07-15 2004-07-08 Board Of Regents Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US8246957B2 (en) 2003-03-27 2012-08-21 Sudhir Paul Lupus antibodies for passive immunotherapy of HIV/AIDS
US8147840B2 (en) * 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
AU2006235507B2 (en) * 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080057075A1 (en) * 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
ES2395333T3 (es) * 2007-05-24 2013-02-12 Glaxosmithkline Biologicals S.A. Composición liofilizada que contiene WT-1 y CPG
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010114629A2 (en) 2009-04-03 2010-10-07 Duke University Formulation
US9402917B2 (en) * 2009-04-03 2016-08-02 Duke University Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions

Similar Documents

Publication Publication Date Title
JP2010523676A5 (enExample)
US5013548A (en) Production of antibodies to HIV
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
US5019387A (en) Production of antibodies to HIV
JP2018502885A5 (enExample)
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
DE60329106D1 (de) Ghrelin-träger-konjugate
JP2013181034A5 (enExample)
JP2007505033A5 (enExample)
PE20071055A1 (es) Anticuerpos anti mn
CN1505528A (zh) 包含结合hiv包膜蛋白的配体的免疫原
Fries et al. HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
JP2013505201A5 (enExample)
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
JP2010523676A (ja) ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
JP2007513992A5 (enExample)
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
Sjölander et al. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-ISCOM preparations. A comparison with other adjuvant systems
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
JP2006528650A5 (enExample)
ATE343592T1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
Xiao et al. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus‐1 envelope protein
MX2011007745A (es) Division de gp41.
Kelker et al. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein